Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Finished Goods (2017 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Finished Goods for 9 consecutive years, with $25.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Finished Goods rose 8.7% to $25.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $25.0 million, a 8.7% increase, with the full-year FY2025 number at $25.0 million, up 8.7% from a year prior.
  • Finished Goods was $25.0 million for Q4 2025 at Ultragenyx Pharmaceutical, up from $23.0 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $26.7 million in Q2 2025 to a low of $4.9 million in Q2 2022.
  • A 5-year average of $13.5 million and a median of $12.1 million in 2023 define the central range for Finished Goods.
  • Peak YoY movement for Finished Goods: dropped 13.08% in 2022, then surged 107.99% in 2023.
  • Ultragenyx Pharmaceutical's Finished Goods stood at $5.7 million in 2021, then skyrocketed by 62.04% to $9.3 million in 2022, then soared by 62.82% to $15.1 million in 2023, then soared by 52.22% to $23.0 million in 2024, then grew by 8.7% to $25.0 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Finished Goods are $25.0 million (Q4 2025), $23.0 million (Q3 2025), and $26.7 million (Q2 2025).